Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
Sarepta Therapeutics (NASDAQ:SRPT), a precision genetic medicine company focusing on rare diseases, has scheduled its third quarter 2024 financial results announcement for Wednesday, November 6, 2024, after the Nasdaq market closes. The company will host a conference call at 4:30 p.m. ET to discuss the results. The event will be webcast live on Sarepta's investor relations website, with a replay available for one year. Phone participants must register online to receive dial-in details and personal PIN numbers for access.
Sarepta Therapeutics (NASDAQ:SRPT), un'azienda di medicina genetica di precisione che si concentra sulle malattie rare, ha programmato l'annuncio dei risultati finanziari del terzo trimestre 2024 per mercoledì 6 novembre 2024, dopo la chiusura del mercato Nasdaq. L'azienda ospiterà una teleconferenza alle 16:30 ora ET per discutere i risultati. L'evento sarà trasmesso in diretta sul sito web delle relazioni con gli investitori di Sarepta, con una registrazione disponibile per un anno. I partecipanti telefonici devono registrarsi online per ricevere le informazioni per il collegamento e i numeri PIN personali per l'accesso.
Sarepta Therapeutics (NASDAQ:SRPT), una empresa de medicina genética de precisión centrada en enfermedades raras, ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 para el miércoles 6 de noviembre de 2024, después del cierre del mercado Nasdaq. La empresa llevará a cabo una llamada de conferencia a las 4:30 p.m. ET para discutir los resultados. El evento se transmitirá en vivo en el sitio web de relaciones con los inversionistas de Sarepta, con una repetición disponible durante un año. Los participantes por teléfono deben registrarse en línea para recibir los detalles de acceso y números PIN personales.
사렙타 테라퓨틱스 (NASDAQ:SRPT)는 희귀 질환에 초점을 맞춘 정밀 유전자 의학 회사로, 2024년 3분기 재무 결과 발표를 2024년 11월 6일 수요일, 나스닥 시장 폐장 후에 예정했습니다. 회사는 오후 4시 30분(동부 표준시)에 결과를 논의하기 위한 컨퍼런스 콜을 진행할 것입니다. 이 행사는 사렙타의 투자자 관계 웹사이트에서 라이브로 웹캐스트되며, 1년 동안 다시 볼 수 있습니다. 전화 참가자는 접속 정보를 얻고 개인 PIN 번호를 받기 위해 온라인으로 등록해야 합니다.
Sarepta Therapeutics (NASDAQ:SRPT), une entreprise de médecine génétique de précision axée sur les maladies rares, a prévu l'annonce de ses résultats financiers du troisième trimestre 2024 pour le mercredi 6 novembre 2024, après la fermeture du marché Nasdaq. L'entreprise organisera une conférence téléphonique à 16h30, heure de l'Est, pour discuter des résultats. L'événement sera diffusé en direct sur le site web des relations avec les investisseurs de Sarepta, avec un enregistrement disponible pendant un an. Les participants par téléphone doivent s'inscrire en ligne pour recevoir les informations d'appel et des numéros PIN personnels pour accéder.
Sarepta Therapeutics (NASDAQ:SRPT), ein Unternehmen für präzise Gentherapie, das sich auf seltene Krankheiten spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das dritte Quartal 2024 auf Mittwoch, den 6. November 2024, nach Marktschluss der Nasdaq angesetzt. Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu erörtern. Die Veranstaltung wird live auf der Investor-Relations-Website von Sarepta gestreamt, mit einem Replay, das ein Jahr lang verfügbar sein wird. Telefonische Teilnehmer müssen sich online registrieren, um die Einwahldaten und persönlichen PIN-Nummern für den Zugang zu erhalten.
- None.
- None.
The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241023549080/en/
Investor:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
FAQ
When will Sarepta Therapeutics (SRPT) release Q3 2024 earnings?
How can I access Sarepta Therapeutics (SRPT) Q3 2024 earnings call?
Where can I find the replay of Sarepta Therapeutics (SRPT) Q3 2024 earnings call?
